|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 March 2002, Vol. 99, No. 6, pp. 1959-1964
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Clinicopathologic analysis of follicular lymphoma occurring
in children
Robert B. Lorsbach,
Dominic Shay-Seymore,
Jennifer Moore,
Peter M. Banks,
Robert P. Hasserjian,
John
T. Sandlund, and
Frederick G. Behm
From the Departments of Pathology and
Hematology/Oncology, St Jude Children's Research Hospital, Memphis,
TN; the Department of Pathology, Carolinas Medical Center, Charlotte,
NC; and the Department of Pathology, Baystate Medical Center,
Springfield, MA.
Follicular lymphoma is a rare lymphoid malignancy in
pediatric patients and consequently remains poorly characterized,
particularly with respect to its immunophenotype and
molecular pathogenesis. A total of 23 pediatric patients with
follicular lymphoma were identified, with a median age of 11 years and
a male-to-female ratio of 2.3:1. Of the 19 patients for whom presenting
clinical features were available, 15 patients had stage I, 1 had stage II, and 3 had stage III or IV disease. All tumors had a follicular architecture, and 74% of cases had grade 2 or 3 histologic features. All patients expressed CD20 and bcl-6, and 80% were positive for CD10.
Bcl-2 expression was detected in only 5 of 16 cases. Consistent with
this finding, bcl-2 gene rearrangements were detected in only 2 of 16 cases by polymerase chain reaction. These patients were treated primarily with cyclophosphamide, doxorubicin, vincristine, and prednisone-based chemotherapy; 4 patients also received
involved-field irradiation. Of the 13 patients with available clinical
follow-up, all but 2 achieved durable clinical remission. Importantly,
all 4 patients with tumors diffusely positive for bcl-2 either
presented with stage III/IV disease or had disease refractory to
therapy, whereas patients with bcl-2-negative tumors uniformly had
stage I disease, achieved complete remission, and experienced no
relapses. These findings indicate that, in contrast to adult follicular lymphomas, dysregulated bcl-2 expression does not play a significant pathogenetic role in most pediatric follicular lymphomas. However, bcl-2 expression in pediatric follicular lymphoma identifies a subset
of patients in whom disease is often disseminated at clinical presentation and is more refractory to combination chemotherapy.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. Ott and A. Rosenwald
Molecular pathogenesis of follicular lymphoma
Haematologica,
December 1, 2008;
93(12):
1773 - 1776.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S. Jaffe, N. L. Harris, H. Stein, and P. G. Isaacson
Classification of lymphoid neoplasms: the microscope as a tool for disease discovery
Blood,
December 1, 2008;
112(12):
4384 - 4399.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Pathology Quiz Case 2 Diagnosis
Arch Otolaryngol Head Neck Surg,
October 1, 2007;
133(10):
1065 - 1066.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Salles
Clinical Features, Prognosis and Treatment of Follicular Lymphoma
Hematology,
January 1, 2007;
2007(1):
216 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T. Sandlund
Should Adolescents with NHL Be Treated as Old Children or Young Adults?
Hematology,
January 1, 2007;
2007(1):
297 - 303.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Oliver, M. B. Miranda, S. Shangary, S. Land, S. Wang, and D. E. Johnson
(-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-XL-mediated apoptosis resistance
Mol. Cancer Ther.,
January 1, 2005;
4(1):
23 - 31.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S A Pileri, E Sabattini, P Rosito, P L Zinzani, S Ascani, G Fraternali-Orcioni, B Gamberi, M Piccioli, D Vivenza, B Falini, et al.
Primary follicular lymphoma of the testis in childhood: an entity with peculiar clinical and molecular characteristics
J. Clin. Pathol.,
September 1, 2002;
55(9):
684 - 688.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
